1. Home
  2. Companies
  3. CYP
  4. Material Events

Cynata Therapeutics (ASX:CYP) — Material Events

ASX:CYP · 14 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 11 articles Notable 3 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
11
Cynata Therapeutics Awaits Pivotal Phase 2 and 3 Trial Results Amid Capital RaiseHigh
Cynata Therapeutics anticipates pivotal trial results in Q2 2026 amid capital raising and sector momentum
30 Apr 2026 ·Quarterly Activity Report and Appendix 4C ·85
Cynata Completes Key Phase 2 Milestone in aGvHD Trial, Data Due JuneMedium
Cynata completes primary evaluation period in Phase 2 aGvHD trial; results expected June 2026
30 Mar 2026 ·Clinical Trial Update ·85
Cynata Therapeutics Poised for Key Trial Results, Extends Cash Runway to Mid-2026Medium
Cynata Therapeutics nears Phase 3 and Phase 2 trial results, strengthens IP, extends cash runway to mid-2026
29 Jan 2026 ·Quarterly Activity Report and Appendix 4C ·85
Cynata Completes Phase 2 Enrolment for Promising aGvHD TherapyMedium
Cynata completes enrolment in Phase 2 trial of CYP-001 for life-threatening aGvHD
15 Dec 2025 ·Clinical Trial Update ·85
Cynata Therapeutics Raises A$1.5 Million Placement Ahead of Key Clinical Trial ReadoutsMedium
Cynata Therapeutics Raises A$1.5 Million Placement Ahead of Key Clinical Trial Readouts
4 May 2026 ·Capital Raising ·85
Cynata Builds Momentum with Three Clinical Trials Nearing Key ReadoutsMedium
Cynata advances multiple clinical trials with key readouts due in 2025-26, maintains solid cash runway
30 July 2025 ·Quarterly Activity Report and Appendix 4C ·85
EMA Paediatric Committee Endorses Cynata’s CYP-001 Trial Plan for aGvHDMedium
Cynata secures EMA positive opinion for paediatric trial plan of CYP-001 in aGvHD
3 June 2026 ·Regulatory Update ·85
Cynata Eyes Pivotal Trial Results and Funding Stability Into Mid-2026Medium
Cynata advances clinical trials with key results due Q2 2026 and secures funding through mid-2026
31 Oct 2025 ·Quarterly Activity Report and Appendix 4C ·85
Cynata Therapeutics Advances Clinical Pipeline Amid $9.39M Loss, Eyes 2026 MilestonesHigh
Cynata Therapeutics reports $9.39M loss, advances clinical trials with key results due in 2026, maintains funding runway through mid-2026
28 Aug 2025 ·Annual Financial Report ·80
Cynata Wraps Final Patient Visit in Pivotal Osteoarthritis TrialMedium
Cynata Completes Final Patient Visit in Phase 3 Osteoarthritis Trial, Results Expected Q2 2026
24 Nov 2025 ·Clinical Trial Update ·80
Cynata Therapeutics Narrows Loss as Key Trials Near Data ReadoutsMedium
Cynata Therapeutics narrows half-year loss, advances clinical trials, extends cash runway to mid-2026
26 Feb 2026 ·Appendix 4D Half Year Report ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.